Phospho-eIF2 alpha (Tyr150) Antibody - #AF7188
製品: | Phospho-eIF2 alpha (Tyr150) Antibody |
カタログ: | AF7188 |
タンパク質の説明: | Rabbit polyclonal antibody to Phospho-eIF2 alpha (Tyr150) |
アプリケーション: | WB IHC |
反応性: | Human, Mouse, Rat |
予測: | Bovine, Horse, Sheep, Dog, Chicken, Xenopus |
分子量: | 38kDa; 36kD(Calculated). |
ユニプロット: | P05198 |
RRID: | AB_2843628 |
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# AF7188, RRID:AB_2843628.
折りたたみ/展開
EIF 2 alpha; EIF 2; EIF 2A; EIF 2alpha; eIF-2-alpha; eIF-2A; EIF-2alpha; EIF2 alpha; EIF2; EIF2A; EIF2S1; Eukaryotic translation initiation factor 2 subunit 1 alpha 35kDa; Eukaryotic translation initiation factor 2 subunit 1 alpha; Eukaryotic translation initiation factor 2 subunit 1; Eukaryotic translation initiation factor 2 subunit alpha; IF2A_HUMAN;
免疫原
- P05198 IF2A_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MPGLSCRFYQHKFPEVEDVVMVNVRSIAEMGAYVSLLEYNNIEGMILLSELSRRRIRSINKLIRIGRNECVVVIRVDKEKGYIDLSKRRVSPEEAIKCEDKFTKSKTVYSILRHVAEVLEYTKDEQLESLFQRTAWVFDDKYKRPGYGAYDAFKHAVSDPSILDSLDLNEDEREVLINNINRRLTPQAVKIRADIEVACYGYEGIDAVKEALRAGLNCSTENMPIKINLIAPPRYVMTTTTLERTEGLSVLSQAMAVIKEKIEEKRGVFNVQMEPKVVTDTDETELARQMERLERENAEVDGDDDAEEMEAKAED
種類予測
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - P05198 基板として
Site | PTM Type | Enzyme | Source |
---|---|---|---|
S5 | Phosphorylation | Uniprot | |
K12 | Ubiquitination | Uniprot | |
S26 | Phosphorylation | Uniprot | |
S49 | Phosphorylation | Q9NZJ5 (EIF2AK3) , Q9BQI3 (EIF2AK1) , P19525 (EIF2AK2) , Q75MR0 (HRI) | Uniprot |
S52 | Phosphorylation | B4DS64 (PRKRIR) , P51812 (RPS6KA3) , P19525 (EIF2AK2) , P28482 (MAPK1) , Q75MR0 (HRI) , Q9BQI3 (EIF2AK1) , Q9NZJ5 (EIF2AK3) , Q05655 (PRKCD) , Q16539 (MAPK14) , Q9P2K8 (EIF2AK4) | Uniprot |
S58 | Phosphorylation | Uniprot | |
K61 | Ubiquitination | Uniprot | |
K80 | Ubiquitination | Uniprot | |
Y82 | Phosphorylation | Uniprot | |
S86 | Phosphorylation | Uniprot | |
K87 | Ubiquitination | Uniprot | |
S91 | Phosphorylation | Uniprot | |
K97 | Ubiquitination | Uniprot | |
K101 | Acetylation | Uniprot | |
K101 | Ubiquitination | Uniprot | |
K104 | Ubiquitination | Uniprot | |
K106 | Ubiquitination | Uniprot | |
S110 | Phosphorylation | Uniprot | |
K123 | Ubiquitination | Uniprot | |
R133 | Methylation | Uniprot | |
K141 | Acetylation | Uniprot | |
K141 | Ubiquitination | Uniprot | |
K143 | Acetylation | Uniprot | |
K143 | Ubiquitination | Uniprot | |
Y147 | Phosphorylation | Uniprot | |
Y150 | Phosphorylation | Uniprot | |
K154 | Methylation | Uniprot | |
K154 | Ubiquitination | Uniprot | |
S158 | Phosphorylation | Uniprot | |
T185 | Phosphorylation | Uniprot | |
K190 | Ubiquitination | Uniprot | |
Y200 | Phosphorylation | Uniprot | |
Y202 | Phosphorylation | Uniprot | |
K209 | Ubiquitination | Uniprot | |
S219 | Phosphorylation | Uniprot | |
K226 | Ubiquitination | Uniprot | |
Y235 | Phosphorylation | Uniprot | |
T245 | Phosphorylation | Uniprot | |
K259 | Ubiquitination | Uniprot | |
K265 | Ubiquitination | Uniprot | |
R266 | Methylation | Uniprot | |
K276 | Ubiquitination | Uniprot | |
T279 | Phosphorylation | Uniprot | |
T281 | Phosphorylation | Uniprot | |
T284 | Phosphorylation | Uniprot | |
K312 | Ubiquitination | Uniprot |
研究背景
Functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S pre-initiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B.
Substrate for at least 4 kinases: EIF2AK1/HRI, EIF2AK2/PKR, EIF2AK3/PERK and EIF2AK4/GCN2. Phosphorylation stabilizes the eIF-2/GDP/eIF-2B complex and prevents GDP/GTP exchange reaction, thus impairing the recycling of eIF-2 between successive rounds of initiation and leading to global inhibition of translation. Phosphorylated; phosphorylation on Ser-52 by the EIF2AK4/GCN2 protein kinase occurs in response to amino acid starvation and UV irradiation (By similarity).
Cytoplasm>Stress granule.
Note: Colocalizes with NANOS3 in the stress granules.
Heterotrimer composed of an alpha, a beta and a gamma chain. Component of an EIF2 complex at least composed of CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5. Interaction with METAP2 protects EIF2S1 from inhibitory phosphorylation (By similarity). Interacts with ABCF1 isoform 2. Associates with ribosomes. Interacts with DDX3X in an RNA-independent manner.
Belongs to the eIF-2-alpha family.
研究領域
· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)
· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)
· Genetic Information Processing > Translation > RNA transport.
· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum. (View pathway)
· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Measles.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.
参考文献
Application: WB Species: Human Sample: HUVECs
Application: WB Species: human Sample: HUVECs
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.